Insilico Medicine vs LightOn
Relationship
Science42: DORA and LightOn Enterprise do comparable work on summarization; both also serve buyers who need to draft and edit written content; smaller scale (public).
Assembled from the recorded fields for this pair, not hand-checked. The comparison below is read from each company’s own profile.
3 of 8 capabilities — Shares knowledge retrieval, summarization and text generation.
Ludbee capability tags · from the product recordsShared product type — Both ship application.
Ludbee product recordsSmaller scale — LightOn: $29.6M market cap, against Insilico Medicine's $4.3B market cap.
Ludbee scale figures · valuation, market cap or revenue estimateAligned comparison
Capability overlap
Shared · 3
Not verified for LightOn · 5
Recorded for Insilico Medicine. LightOn’s product records say nothing either way — a missing record is not a missing capability.
Not verified for Insilico Medicine · 2
Recorded for LightOn. Insilico Medicine’s product records say nothing either way — a missing record is not a missing capability.
Products, side by side
Algorithmic pairing — assembled from recorded fields, not hand-checked
Insilico Medicine
Application
AI research writing assistant that drafts structured, cited papers, reviews, grant proposals and abstracts against biomedical databases such as PubMed and bioRxiv.
Multimodal AI platform that forecasts the probability of success of individual clinical trials and scores alternative trial designs before implementation.
LightOn
Application
Chat interface deployed inside an organisation that answers from its own documents, hosted in the EU.
No counterpart
Insilico Medicine sells these in a stack layer with no product recorded for LightOn yet — nothing on the other side to compare them against.
Platform
AI platform for de novo design and multi-property optimization of peptides, nanobodies and antibodies against specified targets and epitopes.
Generative small-molecule design platform combining de novo generation with physics-based methods, retrosynthesis, ADMET profiling and custom model training.
Foundation-model training and benchmarking platform that fine-tunes a customer's own LLM on Insilico's proprietary pharma reasoning datasets and validates results in its automation lab.
AI platform for therapeutic target identification, biomarker discovery, indication prioritization and drug repurposing over a multi-omics knowledge base.
End-to-end generative-AI platform spanning target discovery, molecular design and clinical-trial risk assessment for pharmaceutical research.
Hardware
On-premise AI appliance running PandaOmics target and biomarker discovery locally with no external data transmission, sold in Server and Desktop editions.
LightOn sells these in a stack layer with no product recorded for Insilico Medicine yet — nothing on the other side to compare them against.
API service
Retrieval API with parse, extract and retrieve endpoints for building document-grounded applications.